Transforming growth factor-β-induced transcription of the Alzheimer β-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads

https://doi.org/10.1016/S0006-291X(02)00725-8Get rights and content

Abstract

Transforming growth factor-β-1 (TGF-β), a key regulator of the brain responses to injury and inflammation, has been implicated in upregulating the expression of the Alzheimer amyloid precursor protein (APP) and Alzheimer's disease (AD) pathogenesis. However, little is known about the mechanisms underlying the effects of TGF-β on APP expression. Analysis of APP promoter activity upstream of the chloramphenicol acetyltransferase reporter gene in normal human astrocytes (NHAs), revealed that the APP promoter binding β (APBβ) site (−93/−82) is responsive to TGF-β. This site interacts with the zinc finger nuclear factor CTCF, involved in APP transcriptional activity. As determined by gel shift assay, there was no significant difference in the CTCF–APBβ complex binding activity in the presence or absence of TGF-β treatment of NHAs. To further investigate the contributions of the CTCF-complex and Smad proteins to the TGF-β induced APP promoter activity, we examined the distribution of these factors and their DNA binding activity. Interestingly, upon TGF-β treatment both Smads 3 and 4 were translocated to the nuclei in contrast to Smad 2, which was cytoplasmic. However, CTCF was predominantly localized in the nuclei irrespective of TGF-β treatment. Gel super shift assay coupled with Western blot analysis showed that Smads 3 and 4 specifically associated with the CTCF–APBβ complex. In addition, AD brain sections showed increased expression and nuclear localization of Smad 4, which correlated with higher levels of APP and TGF-β. However, over expression of Smad 4 on its own was not sufficient to affect APP expression. These results demonstrate that TGF-β activation of Smad protein complexes promotes transcription of the APP gene. Increased synthesis of APP may in part determine production and deposition in affected AD brain.

Section snippets

Materials and methods

Reagents. NHAs and astrocyte growth media were purchased from Clonetics (San Diego). Natural human TGF-β, the Nuclear Protein Extraction Kit (N-xtract) and all other reagents were purchased from Sigma unless otherwise stated. Rabbit polyclonal anti-CTCF type 1 IgG antibody was purchased from Upstate Biotechnology. (Lake Placid, NY), and anti-APP mouse monoclonal (clone 27) antibody to detect APP in AD brain sections was purchased from Zymed. Sheep anti-mouse Ig Texas red-linked whole antibody

Localization of the TGF-β response element to −94/−77 bp of the APP promoter

In the accompanying paper we showed that the proximal, −488 bp fragment of the APP promoter was able to mediate TGF-β effect on APP gene transcription. This proximal promoter region (−488 bp) contains previously characterized nuclear factor binding sites (Fig. 1) that contribute to the promoter activity [5]. To define precisely the TGF-β response element within this domain, deletion constructs of the APP promoter reporter CAT plasmid (−488, −94, −77) and the longest full-length construct −2832

Discussion

Several studies in transgenic mice underscore the potential relevant interactions between TGF-β and APP in the development or progression of AD. In all forms of AD, the abnormal accumulation of Aβ in the brain appears crucial to neurodegeneration. Increased Aβ production and deposition may be largely determined both by synthesis and the subsequent post-translational proteolytic processing of APP. Thus, it is important to study the factors and underlying mechanisms that affect APP synthesis. One

Acknowledgements

We thank Dr. Wolfgang, W. Quitschke, and Dmitry Goldgaber for providing the APP plasmids; Robert Fandrich and Bradley Doble for their excellent technical assistance. We gratefully acknowledge the National Neurological Research Specimen Bank for providing brain tissues. This work was supported by grants from the Scottish Rite Charitable Foundation of Canada and the St. Boniface Hospital Research Foundation.

References (53)

  • R.L. Neve et al.

    Neuron

    (1988)
  • W.W. Quitschke

    J. Biol. Chem

    (1994)
  • A.A. Vostrov et al.

    J. Biol. Chem.

    (1997)
  • C.W. Gray et al.

    Mol. Brain Res.

    (1993)
  • M.P. Mattson et al.

    Brain Res. Brain Res. Rev.

    (1997)
  • U. Mönning et al.

    FEBS Lett.

    (1994)
  • U. Mönning et al.

    J. Biol. Chem.

    (1995)
  • S. Itagaki et al.

    J. Neuroimmunol.

    (1989)
  • K.C. Flanders et al.

    Prog. Neurobiol.

    (1998)
  • L. Attisano et al.

    Curr. Opin. Cell. Biol.

    (1998)
  • R. Derynck

    Trends Biochem. Sci.

    (1994)
  • J.L. Wrana et al.

    Cell

    (1992)
  • M. Macias-Silva et al.

    Cell

    (1996)
  • C. Pouponnot et al.

    J. Biol. Chem.

    (1998)
  • C.B. Rich et al.

    J. Biol. Chem.

    (1996)
  • P. Vandenabeele et al.

    Immunol. Today

    (1991)
  • P. Pollwein

    Biochem. Biophys. Res. Commun.

    (1993)
  • W.W. Quitschke et al.

    J. Biol. Chem.

    (1996)
  • A.A. Vostrov et al.

    J. Biol. Chem.

    (2002)
  • M.D. Delgado et al.

    FEBS Lett.

    (1999)
  • M.L. Cohen et al.

    Proc. Natl. Acad. Sci. USA

    (1988)
  • S.A. Johnson et al.

    Science

    (1990)
  • K. Hsiao et al.

    Science

    (1996)
  • A.A. Vostrov et al.

    Nucl. Acids Res.

    (1995)
  • E.A. van der Wal et al.

    NeuroReport

    (1993)
  • N.S. Peress et al.

    J. Neuropathol. Exp. Neurol.

    (1995)
  • Cited by (0)

    Abbreviations: AD, Alzheimer's disease; APP, amyloid precursor protein; Aβ, amyloid β-peptide; NHA, normal human astrocytes; TGF-β1, transforming growth factor-β; CTCF, CTC rich sequence zinc finger domain transcription factor; Smad, vertebrate homologous of Sma and Mad genes; CAT, chloramphenicol acetyltransferase; β-Gal, β-galactosidase.

    View full text